Jupiter Neurosciences, Inc.
JUNS Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.86
KIRA · Stoqly’s AI analyst, in plain words
- Jupiter Neurosciences, Inc. had $0.0M of revenue in fiscal 2025.
- Its operating margin was −40,865.6%: of every 100 in sales, about −40,866 is left after running the business.
- Jupiter Neurosciences, Inc. lost $8.6M in fiscal 2025.
Market cap
$1.6M
P/E
3.8x
Revenue
$0.0M
Net income
−$8.6M
Free cash flow
—
Operating margin
−40,865.6%
Jupiter Neurosciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−39,655.5%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
3.8x
One share costs 3.8 times its yearly profit per share.
What Jupiter Neurosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 1, 2026
- Legal name
- JUPITER NEUROSCIENCES, INC.
- CIK
- 0001679628
Jupiter Neurosciences, Inc. · JUNS
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | — | $0.0M | $0.0M |
| Gross margin | — | — | 80.7% |
| Operating margin | — | — | −40,865.6% |
| Net income | −$4.8M | −$2.4M | −$8.6M |
| Net margin | — | — | −39,655.5% |
| Diluted EPS | −$0.18 | −$0.08 | −$0.25 |
| Cash | |||
| Cash from operations | −$0.5M | −$3.9M | −$5.4M |
| Share count change | — | 9.0% | 20.3% |
| Debt and strength | |||
| Cash and short-term investments | $0.0M | $3.8M | $3.8M |
| Shareholders' equity | −$5.8M | $4.2M | −$1.8M |
| Current ratio | 0.0x | 2.3x | 0.7x |
| Interest coverage | −17.7x | −12.4x | −135.0x |
| Returns and quality | |||
| Return on equity | — | — | −738.8% |
| Return on tangible equity | — | −58.5% | — |
| Piotroski F-score | — | — | 2 |
| Altman Z'' | −947.0 | −12.1 | −34.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Jupiter Neurosciences, Inc. · JUNS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.86 a share, the company is worth $1.6M: 3.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001679628). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.